about
Dyspnoea in a young woman: the opposite of every truth is just as true.The role of platelets in antiphospholipid syndrome.Interpretation of laboratory data and need for reference laboratories.A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial FibrillationCancer prevention and vitamin K antagonists: an overview.What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?Correct laboratory approach to APS diagnosis and monitoring.Investigational anticoagulants for hematological conditions: a new generation of therapies.Antiphospholipid syndrome and the heart: a case series and literature review.Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.APS - Diagnostics and challenges for the future.Laboratory testing for antiphospholipid syndrome.To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant.Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile.Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma.Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases.Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study.Primary thromboprophylaxis with low-dose aspirin and antiphospholipid antibodies: Pro's and Con's.The paradox of the lupus anticoagulant: history and perspectives.The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis.Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT).Effectiveness and safety of oral anticoagulation with non-vitamin K antagonists compared to well-managed vitamin K antagonists in naïve patients with non-valvular atrial fibrillation: Propensity score matched cohort study.Thrombocytopenia in high-risk patients with antiphospholipid syndrome.Laboratory Diagnostics of Antiphospholipid Syndrome.An approach to differential diagnosis of antiphospholipid antibody syndrome and related conditionsPrevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA)Long-term use of vitamin K antagonists and incidence of cancer: a population-based studyAn unusual acute coronary syndrome: undisclosed disease hidden under a confounding clinical presentationAntiphospholipid syndrome: critical analysis of the diagnostic pathAntibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS)Circulating β2 glycoprotein I-IgG anti-β2 glycoprotein I immunocomplexes in patients with definite antiphospholipid syndromeCancer as a risk factor for stroke in atrial fibrillation patients receiving long-term oral anticoagulant therapyDiagnosis and therapy of antiphospholipid syndromeAntiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at riskAntibodies to Domain 4/5 (Dm4/5) of β2-Glycoprotein 1 (β2GP1) in different antiphospholipid (aPL) antibody profilesConsequences of warfarin suspension after major bleeding in very elderly patients with non valvular atrial fibrillationA Bridging Protocol in High-Thrombotic Risk Mechanical Valve Bearers Undergoing Surgery or Invasive ProceduresRivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome
P50
Q33425705-E1947B20-D59E-4C67-BDBF-9BD1F617C1E9Q33439904-DF013704-B9A0-4D9D-BDBE-8E5007910A73Q34283606-F374B23F-2374-4CB5-A50E-EE2623231033Q35879764-D735E4CA-3654-41BE-BAE9-E3C560FA8541Q37740293-6752B5AB-58E0-425B-8442-50B9EABB75D4Q37991555-77EC3C23-627E-453C-9042-65E492B96A26Q38065593-9AF90B5E-B5E6-4021-83EF-824FD9CB2449Q38123237-D054C13E-EF62-4E3D-A89B-91124B61E193Q38280840-D4A4AE6D-F8A6-4D8B-91C0-B3EAE71753FDQ38389058-F327AF53-E5A2-4271-9125-350E8A211A93Q38807555-763EF623-ECCF-422F-ABC4-BBC3169393C9Q38830480-3C093C98-A4E4-4474-8C22-2CAFC9B30233Q41036908-8BEF4486-55B5-46DB-B7A4-BEEEE6CB5015Q41222650-17E293DB-6C0C-4CF1-BD52-9A554430ECA6Q41747738-BDA435F2-1BEF-4347-9508-F2280B3501EEQ45383876-B1F22F53-C4ED-42C6-88A8-F70DABF057A2Q45873657-8702A877-BF8A-4B5E-B5DC-A3B98AB652B0Q46704454-0A043B38-08CC-4561-83E9-ADE921E17E83Q47182646-75E1BEF6-9ED7-4444-A919-371E64117DDAQ47983231-911D8B01-AACE-418E-A850-71F6F416D88FQ48060132-8E6EB7D8-DFE8-4A8B-B240-5D688D422884Q48384587-B653D6B3-EB02-4CF6-8842-0502BE315C93Q48605371-3AC01C54-B19F-49EE-90F5-16AFDC993F56Q49955474-F213E630-D687-4441-8222-0DD9E01B67D6Q50112309-4777AC26-4F27-4175-A88C-49EF902D6D2FQ51021148-31DEDC9A-C893-4D9A-8FDE-394E2E74D8EDQ59075500-97E2676C-E285-4870-93A7-EE6ED0B37329Q61928679-EC643BE3-6267-4DD5-B4B6-EA0717349B15Q82714386-88A8D8BD-5530-45C7-A847-C01BA3718B6FQ83789628-9FA1B102-6D1D-4498-9A48-8955F75E56F6Q83954306-FDA34542-F97E-4A6B-9BF6-3A74AF7D0DEDQ84212281-812C8F19-C623-48AE-9F2A-A33702D89E62Q84227566-6BD5DD44-CDA1-4026-929F-A2E8B6FECD48Q85473529-99B679D2-0F42-4CB9-A6D3-F0E9CB23485DQ85980277-50DEACD4-598F-4FEC-9AFD-DA2503B29478Q86646346-7726B805-8735-4E16-9CF9-62AC24CE6671Q87279480-805E0000-B5C7-4334-97A5-EB9F1767DBBBQ88563255-4B5815D0-3AD9-4EFB-91CF-20AF98A47FA4Q88987242-82B51B33-FA9A-463E-9ACD-96862D473E4AQ90007363-278AD940-C909-4BC4-83C9-657CD62EE998
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
G Denas
@ast
G Denas
@en
G Denas
@es
G Denas
@nl
type
label
G Denas
@ast
G Denas
@en
G Denas
@es
G Denas
@nl
prefLabel
G Denas
@ast
G Denas
@en
G Denas
@es
G Denas
@nl
P106
P1153
23970221500
P31
P496
0000-0001-6484-0007